Health Catalyst, INC Form 4 insider transactions

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 16,902 shares of common stock at a price of $4.5161 per share on March 5, 2025, under a pre-arranged 10b5-1 trading plan.

Daniel LeSueur, COO of Health Catalyst, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Benjamin Landry, General Counsel of Health Catalyst, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Jason Alger, CFO of Health Catalyst, Inc., sold 7,304 shares of common stock on March 3, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, sold 10,800 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Health Catalyst CEO Daniel D. Burton sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Julie Larson-Green, a director at Health Catalyst, Inc., reported acquiring 2,450 shares of common stock on March 1, 2025, through the vesting of restricted stock units.

Director Duncan Gallagher reports acquiring 3,033 shares of Health Catalyst, Inc. common stock through vested restricted stock units.

Daniel D. Burton, CEO of Health Catalyst, Inc., received awards of restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) on February 20, 2025, according to a Form 4 filing.

Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, Inc., received awards of restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) on February 20, 2025.

Jason Alger, CFO of Health Catalyst, reports the acquisition of common stock and restricted stock units, increasing his beneficial ownership in the company.

Benjamin Landry, General Counsel of Health Catalyst, reports the acquisition of restricted stock units and performance-based restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., received awards of restricted stock units and performance-based restricted stock units.

Daniel LeSueur, COO of Health Catalyst, reports the acquisition of common stock and restricted stock units (RSUs) and performance-based restricted units (PRSUs) on February 20, 2025.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 6,441 shares of common stock at a price of $5.4266 per share on February 18, 2025, under a pre-arranged trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at a price of $5.7607 per share on February 5, 2025, under a pre-arranged trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, sold 6,442 shares of common stock at $5.7976 per share on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at $7.5128 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Health Catalyst's General Counsel, Benjamin Landry, sold 2,500 shares of common stock at $7.5182 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Director Duncan Gallagher of Health Catalyst, Inc. sold 4,500 shares of common stock at a price of $6.9298 per share on December 30, 2024.

Health Catalyst director Duncan Gallagher sold 4,500 shares of common stock at $6.9812 per share on December 23, 2024, under a pre-arranged 10b5-1 trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 6,442 shares of common stock at a price of $7.8848 per share on December 16, 2024, under a pre-arranged trading plan.

Health Catalyst's Chief Financial Officer, Jason Alger, sold 19,599 shares of common stock at a price of $8.3193 per share, totaling $86,712, under a pre-arranged trading plan.

Health Catalyst's General Counsel, Benjamin Landry, sold 19,268 shares of common stock at a price of $8.3192 per share, totaling $72,250, under a pre-arranged trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 22,773 shares of common stock at a price of $7.6952 per share on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

Director Jill Hoggard Green of Health Catalyst, Inc. was granted 27,706 restricted stock units (RSUs) on December 1, 2024, which will vest over three years.

Health Catalyst's Chief Financial Officer, Jason Alger, sold 7,795 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

A Health Catalyst executive sold shares to cover tax obligations from vesting restricted stock units and also executed a planned sale under a pre-arranged trading plan.

Health Catalyst's General Counsel, Benjamin Landry, sold 9,419 shares of common stock to cover tax obligations related to vesting restricted stock units.